SB 204741

Research use only, not for human use.

5-HT2B receptor antagonist.

5-HT2B receptor antagonist.

The most selective 5-HT2B receptor ligand to be tested is SB 204741 with approximately 20 fold selectivity for the human 5-HT2B receptor as compared to the human 5-HT2C receptor.

SB-204741 (0.25~1.0 mg/kg; i.p.) induces myocardial remodeling and dose dependently improves hemodynamic and ventricular functions following isoproterenol-induced myocardial injury.SB-204741 bolsters endogenous anti-oxidant enzymes activities, improves cardiac injury markers, NO level and lipid peroxidation level and attenuates TNFα level in isoproterenol-induced myocardial remodeling in rats. SB-204741 (0.5 and 1.0 mg/kg/day) pre-treatment for 28 days significantly amplifies NO level and GSH and SOD activities and attenuates TBARS level following isoproterenol-induced myocardial remodeling. SB-204741 inhibits inflammatory protein expression, upregulates autophagy and HSPs protein expressions in isoproterenol-induced myocardial remodeling in rats. SB-204741 improves myocardial architecture in isoproterenol-induced myocardial remodeling in rats. Animal Model:Rats Dosage:0.25~1.0 mg/kg Administration:I.p. Result:Induced myocardial remodeling.

——

Endocrinology/Hormones

5-HT Receptor

5-HT2B

——

——

152239-46-8

286.35

C14H14N4OS

>98% (HPLC)

Ethanol:<5.73mg/ml;DMSO:<28.64mg/ml

Cc1nsc(NC(Nc(cc2)cc3c2n(C)cc3)=O)c1

——

(-20℃)

With Ice Pack

≥ 2 years